2 March 2018 - - Thousand Oaks, California-based human therapeutics developer Amgen (NASDAQ: AMGN) will present new data from the Repatha (evolocumab) clinical trial program at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Fla., March 10-12, 2018, the company said.
FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a multinational Phase 3 randomized, double-blind, placebo-controlled trial, is designed to evaluate whether treatment with Repatha in combination with high- or moderate-intensity statin therapy compared to placebo plus statin therapy reduces cardiovascular events.
GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) is a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial designed to evaluate the effect of Repatha on the change in burden of coronary artery disease in 968 patients undergoing clinically indicated coronary angiogram and on optimized background statin therapy.
Repatha (evolocumab), a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein receptor, preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.1
Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Its research into cardiovascular disease, and potential treatment options, is part of a growing competency at Amgen that utilizes human genetics to identify and validate certain drug targets.
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.